Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib combined with vinorelbine for previously treated advanced lung cancer with neuroendocrine immunophenotype
ChiCTR2200058151Phase 4Not yet recruiting
- Sponsor
- Anhui Chest Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib and vinorelbine in bronchial carcinoma, sponsored by Anhui Chest Hospital. Primary endpoints: Median progression-free survival, Disease control rate and 3 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
surufatinibvinorelbine
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2200058151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058151.